Bayer Aktiengesellschaft

Michael Kayser

Rainer Gross

Matthias Schramm

Martin Bechem

Gerhard Franckowiak

Gunther Thomas

Elisabeth Perzborn

Friedel Seuter

Gunter Thomas

Siegfried Goldmann

Horst Meyer

Jurgen Stoltefuss

Siegbert Hebisch

Albrecht Marhold

Ulrich Rosentreter

Eckhard Schwenner

Andreas Knorr

Stanislav Kazda

Gunther Kinast

Fred R Heiker

Bernd Pelster

Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,

Circulation-active dioxyalkylenearyl-dihydropyridines

4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,

Circulation active 4-aminoaryldihydropryidine lactones

Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine and

Circulation-active fluoromethoxyphenyl dihydropyridine compounds

A benzylaminoaryl-dihydropyridinelactone compound of the formula (I) ##STR1## in which R.sup.1 represents hydrogen, halogen, cyano, nitro, C.sub.6 -C.sub.12 -aryl, C.sub.1 -C.sub.8 -alkyl, C.sub.1 -C.sub.8 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethoxy, di-C.sub.1 -C.sub.5 -alkylamino, C.sub.1 -C.sub.6 -alkoxycarboxyl or C.sub.1 -C.sub.6 -alkylsulphonyl,

Benzylaminoaryl-dihydropyridinelactones and their use in medicaments

Novel circulation-active cyclohexenecarboxylates of the formula ##STR1## in which R.sup.1 is an organic radical,

Circulation-active cyclohexenecarboxylates

Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, and

[4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl

For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, or

Circulation-active substituted 5-nitro-1,4-dihydropyridines

For the control of coronary diseases and thromboses there are provided the novel compounds ##STR1## in which R.sup.1 is an optionally substituted phenyl or heterocyclic radical,

Substituted 1,4-dihydropyridines for control of circulation and

Circulation active, e.g. antihypertensive novel methionine-substituted dihydropyridines of the formula ##STR1## in which R.sup.1 is phenyl or a heterocyclic radical, or a physiologically acceptable salt thereof.

Circulation active methionine-substituted 1,4-dihydropyridines

Circulation-active 4-aminoaryldihydropyridine lactones

5-Aryl-1,4-dihydropyridines of the formula ##STR1## in which R

Circulation active novel 5-aryldihydropyridines

Novel cardioactive compounds of the formula ##STR1## in which R.sup.1 is alkyl, aryl or heterocyclic, preferably substituted phenyl,

Circulation-active 3-amino-dihydropyridines

Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is optionally substituted aryl or heterocyclic,

Circulation-active 1,4-dihydropyridine derivatives and use thereas

1,4-Dihydropyridine-3-carboxylic acid piperazides of the formula ##STR1## in which R.sup.1 is CN or alkyl, preferably methyl,

Growing community of inventors

Hagen, Germany

Michael Kayser